Peripheral blood smear from a patient with known chronic lymphocytic leukemia (CLL) showing autoimmune hemolytic anemia (AIHA). Brightfield microscopy of Wright-Giemsa stained smear at 1000x (oil immersion) reveals two dominant cell populations: numerous small mature lymphocytes typical of CLL and red blood cells showing spherocytic deformation. A smudge cell is evident just left of center, a classical clue for CLL. Red cells display reduced central pallor consistent with spherocytes, indicating intravascular or extravascular hemolysis driven by autoantibodies. The background shows mild polychromasia and rare nucleated RBCs, consistent with a robust reticulocyte response; the corrected reticulocyte count in this case is markedly elevated (>7%). Platelets are not significantly abnormal. These features collectively support autoimmune destruction of erythrocytes in the setting of CLL. Diagnostic significance lies in recognizing AIHA as a common autoimmune complication in CLL, with a clinical picture of sudden Hb decline and compensatory erythropoiesis. Differential considerations include drug-induced hemolysis, other causes of hemolytic anemia, or marrow infiltration by CLL. Clinical correlation includes therapy implications (steroids, rituximab) and close monitoring of hemolysis markers. This image is a valuable teaching resource for hematology morphology, AIHA in CLL, and differential diagnosis in anemia.

Peripheral blood smear prepared with Wright-Giemsa stain and examined under brightfield illumination using a 100× oil immersion objective reveals a single large plasma cell among a field of mature erythrocytes. The plasma cell displays features typical of clonal plasma cells: basophilic cytoplasm, an eccentrically placed round nucleus, and a conspicuous perinuclear hof; background shows rouleaux formation of red cells. This image exemplifies hematologic involvement by a plasma cell dyscrasia. In plasma cell leukemia, circulating plasma cells constitute more than 20% of leukocytes, a hallmark distinguishing it from conventional multiple myeloma, although both conditions share monoclonal plasma cell proliferation. The presence of circulating plasma cells is associated with younger patient age, higher incidence of anemia, thrombocytopenia, organomegaly, and possible lymphadenopathy; however lytic bone lesions may be less common. Immunophenotypic patterns often include lack of CD56 expression relative to myeloma. Clinically, this morphological finding warrants confirmation with complete blood count, peripheral smear review, quantitative plasma cell percentage, serum protein electrophoresis, and immunofixation to identify monoclonal immunoglobulin isotype (IgD/IgE or light-chain predominance). Early detection of circulating plasma cells supports prognosis assessment and guides therapy decisions in plasma cell dyscrasia management and monitoring, including risk stratification and treatment response evaluation for practice in clinics.

This composite image consists of clinical photographs and a diagnostic peripheral blood smear. Figure 1a (left) shows a pediatric patient with clinical signs including total alopecia (complete absence of scalp hair) and nail pitting affecting both hands and feet, characterized by small punctate depressions on the nail plates. Figure 1b (right) is a microscopic view of a peripheral blood smear demonstrating microangiopathic hemolytic anemia. Visible are numerous schistocytes—fragmented, irregular red blood cells including helmet cells and triangular forms—alongside some normal erythrocytes showing central pallor. The educational focus is on the multi-systemic manifestations of a medical condition, likely a microangiopathic process such as Hemolytic Uremic Syndrome (HUS) or similar systemic pathology, illustrating the correlation between dermatological signs (hair and nail changes) and hematological abnormalities (hemolysis and schistocytosis).

Educational figure illustrating hematological abnormalities in a murine model of Prkab1 deficiency, serving as a surrogate for studying human hemolytic anemia and microcytosis. Panels A-F present dot plots of hematological indices for wild-type (Prkab1+/+) and deficient (Prkab1tm1b/tm1b) mice, showing significant reductions in hemoglobin (A), hematocrit (B), and mean corpuscular volume (E), with a concomitant increase in red blood cell distribution width (F), indicating microcytic anemia with anisocytosis. Panel G contains high-resolution Scanning Electron Microscopy (SEM) images comparing erythrocyte morphology; wild-type cells show standard biconcave discocyte morphology, whereas Prkab1-deficient cells exhibit poikilocytosis with numerous abnormal forms, including acanthocytes, schistocytes, and echinocytes with irregular surface protrusions. Panel H displays an osmotic resistance curve, where Prkab1-deficient erythrocytes demonstrate a left-ward shift, signifying increased osmotic resistance (delayed hemolysis) compared to wild-type controls. The inset confirms a lower NaCl percentage required for 50% hemolysis in deficient cells, indicating altered membrane stability.

A pathophysiology diagram illustrating the 'Inflammaging' concept and its relationship with iron dyshomeostasis and ferroptosis in an aging cell. The diagram is divided into three functional areas: 1) Inflammaging (left), composed of Immunosenescence (reduced M, MQ, NK, B, and CD4+ T cells) and Pro-Inflammation (upregulation of TNF-α, IL-1, IL-6, COX2, iNOS, and NF-κB). 2) Intracellular Aging Cell environment (center), showing a redox imbalance characterized by decreased antioxidants (GPX4, GSH) and increased Reactive Oxygen Species (ROS) accumulation. This environment triggers Hepcidin induction, which inhibits iron export via Ferroportin (FPN). 3) Systematic Consequences (right), where increased intracellular iron facilitates the Fenton reaction and lipid peroxidation, leading to ferroptosis. This cycle results in decreased serum iron (iron deficiency anemia), increased frailty, debility, and accelerated aging. The diagram uses flow arrows to link cellular mechanisms to systemic clinical outcomes, highlighting the synergistic role of chronic inflammation and impaired iron metabolism in aging pathology.

COR	LOE	RECOMMENDATIONS
Management of Anemia or Iron Deficiency
2a	B-R	1. In patients with HFrEF and iron deficiency with or without anemia, intravenous iron replacement is reasonable to improve functional status and QOL (1-4).
3: Harm	B-R	2. In patients with HF and anemia, erythropoietin-stimulating agents should not be used to improve morbidity and mortality (5,6).
Management of Hypertension
1	C-LD	3. In patients with HFrEF and hypertension, uptitration of GDMT to the maximally tolerated target dose is recommended (7,8).
Management of Sleep Disorders
2a	C-LD	4. In patients with HF and suspicion of sleep-disordered breathing, a formal sleep assessment is reasonable to confirm the diagnosis and differentiate between obstructive and central sleep apnea (9,10).
2a	B-R	5. In patients with HF and obstructive sleep apnea, continuous positive airway pressure may be reasonable to improve sleep quality and decrease daytime sleepiness (9,11-13).
3: Harm	B-R	6. In patients with NYHA class II to IV HFrEF and central sleep apnea, adaptive servo-ventilation causes harm (11,12).
Management of Diabetes
1	A	7. In patients with HF and type 2 diabetes, the use of SGLT2i is recommended for the management of hyperglycemia and to reduce HF-related morbidity and mortality (14-17).